{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:02:12Z","timestamp":1780614132856,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41440-026-02596-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:45:58Z","timestamp":1776768358000},"page":"1912-1923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remnant cholesterol level modified the effects of intensive systolic blood pressure lowering treatment in high-risk hypertensive patients: a post hoc analysis of the ESPRIT trial"],"prefix":"10.1038","volume":"49","author":[{"given":"Haixu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhan","family":"Bilige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2596_CR1","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"2596_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"2596_CR3","doi-asserted-by":"publisher","first-page":"e2128980","DOI":"10.1001\/jamanetworkopen.2021.28980","volume":"4","author":"AJ Foy","year":"2021","unstructured":"Foy AJ, Filippone EJ, Schaefer E, Nudy M, Ruzieh M, Dyer AM, et al. Association between baseline diastolic blood pressure and the efficacy of intensive vs standard blood pressure-lowering therapy. JAMA Netw Open. 2021;4:e2128980.","journal-title":"JAMA Netw Open"},{"key":"2596_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/eurjpc\/zwae001","volume":"31","author":"R Yang","year":"2024","unstructured":"Yang R, Zhang J, Yu X, Yang G, Cai J. Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial. Eur J Prev Cardiol. 2024;31:997\u20131004.","journal-title":"Eur J Prev Cardiol"},{"key":"2596_CR5","doi-asserted-by":"publisher","first-page":"e036719","DOI":"10.1161\/JAHA.124.036719","volume":"14","author":"W Zheng","year":"2025","unstructured":"Zheng W, Li S, Jiang C, Hao W, Ai H, Wang X, et al. Effect of intensive blood pressure control and comorbidity status on the prognosis of patients with hypertension: insights from SPRINT. J Am Heart Assoc. 2025;14:e036719.","journal-title":"J Am Heart Assoc"},{"key":"2596_CR6","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"2596_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/2047487318800741","volume":"26","author":"A Attar","year":"2019","unstructured":"Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. Eur J Prev Cardiol. 2019;26:238\u201345.","journal-title":"Eur J Prev Cardiol"},{"key":"2596_CR8","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/HYPERTENSIONAHA.125.25162","volume":"82","author":"X Dong","year":"2025","unstructured":"Dong X, Ling Q, Zhao X, Song Q, Cai J. Benefit and harm of intensive blood pressure control by cardiovascular risk. Hypertension. 2025;82:1392\u20131400.","journal-title":"Hypertension"},{"key":"2596_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743\u201353.","journal-title":"Circulation"},{"key":"2596_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40:537\u201357.","journal-title":"Endocr Rev"},{"key":"2596_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309.","journal-title":"Circulation"},{"key":"2596_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","volume":"288","author":"A Langsted","year":"2020","unstructured":"Langsted A, Madsen CM, Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk. J Intern Med. 2020;288:116\u201327.","journal-title":"J Intern Med"},{"key":"2596_CR13","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42:4324\u201332.","journal-title":"Eur Heart J"},{"key":"2596_CR14","doi-asserted-by":"publisher","unstructured":"Zhu X, Xu W, Hao B, Chen Q, Xiong Z, Wang Q, et al. Variations in remnant cholesterol and the risk of cardiovascular disease: a national longitudinal cohort study. Eur J Prev Cardiol. 2025 (e-pub ahead of print 2025\/09\/22; https:\/\/doi.org\/10.1093\/eurjpc\/zwaf598.","DOI":"10.1093\/eurjpc\/zwaf598"},{"key":"2596_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404:245\u201355.","journal-title":"Lancet"},{"key":"2596_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ahj.2022.12.003","volume":"257","author":"J Liu","year":"2023","unstructured":"Liu J, Wang B, Li Y, Yan X, Ge J, Li J. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): a multicenter open-label randomized controlled trial. Am Heart J. 2023;257:93\u2013102.","journal-title":"Am Heart J"},{"key":"2596_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","volume":"55","author":"AS Levey","year":"2010","unstructured":"Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622\u20137.","journal-title":"Am J Kidney Dis"},{"key":"2596_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud MJ, Hern\u00e1n MA. Why test for proportional hazards? Jama. 2020;323:1401\u20132.","journal-title":"Jama"},{"key":"2596_CR19","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944\u201358.","journal-title":"Eur Heart J"},{"key":"2596_CR20","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.jacc.2023.08.027","volume":"82","author":"KK Patel","year":"2023","unstructured":"Patel KK, McGhie AI, Kennedy KF, Thompson RC, Spertus JA, Sperry BW, et al. Impact of positron emission tomographic myocardial perfusion imaging on patient selection for revascularization. J Am Coll Cardiol. 2023;82:1662\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"2596_CR21","doi-asserted-by":"publisher","unstructured":"Nordestgaard AT, Nordestgaard BG. Remnant cholesterol lowering in cardiovascular disease risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials: meta-regression analyses. Eur J Prev Cardiol. 2025; https:\/\/doi.org\/10.1093\/eurjpc\/zwaf337.","DOI":"10.1093\/eurjpc\/zwaf337"},{"key":"2596_CR22","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.5551\/jat.ED205","volume":"29","author":"H Ohmura","year":"2022","unstructured":"Ohmura H. Contribution of remnant cholesterol to coronary atherosclerosis. J Atheroscler Thromb. 2022;29:1706\u20138.","journal-title":"J Atheroscler Thromb"},{"key":"2596_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Prim. 2019;5:56.","journal-title":"Nat Rev Dis Prim"},{"key":"2596_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1161\/01.CIR.87.4.1179","volume":"87","author":"GC Cheng","year":"1993","unstructured":"Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation. 1993;87:1179\u201387.","journal-title":"Circulation"},{"key":"2596_CR25","doi-asserted-by":"publisher","first-page":"1603907","DOI":"10.3389\/fendo.2025.1603907","volume":"16","author":"F Wang","year":"2025","unstructured":"Wang F, Li Q. Association between residual cholesterol and vulnerable non-culprit lesions progressing to major adverse cardiovascular events. Front Endocrinol. 2025;16:1603907.","journal-title":"Front Endocrinol"},{"key":"2596_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/brv.12939","volume":"98","author":"R Spake","year":"2023","unstructured":"Spake R, Bowler DE, Callaghan CT, Blowes SA, Doncaster CP, Ant\u00e3o LH, et al. Understanding \u2018it depends\u2019 in ecology: a guide to hypothesising, visualising and interpreting statistical interactions. Biol Rev Camb Philos Soc. 2023;98:983\u20131002.","journal-title":"Biol Rev Camb Philos Soc"},{"key":"2596_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","volume":"12","author":"BG Nordestgaard","year":"1992","unstructured":"Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb. 1992;12:6\u201318.","journal-title":"Arterioscler Thromb"},{"key":"2596_CR28","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","volume":"44","author":"E Bj\u00f6rnson","year":"2023","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Rawshani A, Bor\u00e9n J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44:4186\u201395.","journal-title":"Eur Heart J"},{"key":"2596_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12944-020-01311-w","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen J, Kuang J, Tang X, Mao L, Guo X, Luo Q, et al. Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance. Lipids Health Dis. 2020;19:132.","journal-title":"Lipids Health Dis"},{"key":"2596_CR30","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","volume":"76","author":"O Casta\u00f1er","year":"2020","unstructured":"Casta\u00f1er O, Pint\u00f3 X, Subirana I, Amor AJ, Ros E, Hern\u00e1ez \u00c1, et al. Remnant cholesterol, Not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76:2712\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"2596_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"2596_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/00004872-200304000-00013","volume":"21","author":"CM Lawes","year":"2003","unstructured":"Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707\u201316.","journal-title":"J Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02596-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:02:50Z","timestamp":1780610570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02596-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02596-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JLi reports research grants from Servier (TIANJIN) Pharmaceutical for assessing effects of indapamide sustained release and perindopril amlodipine, to the Fuwai Hospital, and honoraria for presentation from Servier (TIANJIN) Pharmaceutical. All other authors report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}